Ablation

New York Liver and Pancreatic Cancer Surgeon, Dr. Dmitri Alden, Now Using New Medtronic Navigation System, The Emprint™ SX, for Liver Tumor Ablations

Retrieved on: 
Friday, May 5, 2023
St. Vincent's Hospital, CT, Ablation, University, 3D, First Moscow State Medical University, Pancreas, SX, Medical school, CHB, Saint Vincent, Liver transplantation, MRI, Medtronic, Publication, Patient, Risk, Cancer, Liver, Neoplasm, Navigation, Hospital, New York Medical College, Medical imaging

NEW YORK, May 5, 2023 /PRNewswire-PRWeb/ -- Dr. Dmitri Alden is a board-certified, world-renowned oncologist and surgeon of the liver, pancreas and biliary system, treating patients from all over the globe. Widely recognized in his field as one of the top specialists in the country, Dr. Alden is always at the forefront of medical innovation. His practice is proud to now offer patients the revolutionary Emprint™ SX ablation platform with Thermosphere™ technology by Medtronic. The Emprint™ SX ablation platform combines real-time, 3D ultrasound and patented Thermosphere™ technology to treat non-resectable liver tumors. The combination of these helps to increase target accuracy and complete tumor coverage with adequate margins.

Key Points: 
  • NEW YORK, May 5, 2023 /PRNewswire-PRWeb/ -- Dr. Dmitri Alden is a board-certified, world-renowned oncologist and surgeon of the liver, pancreas and biliary system, treating patients from all over the globe.
  • Widely recognized in his field as one of the top specialists in the country, Dr. Alden is always at the forefront of medical innovation.
  • His practice is proud to now offer patients the revolutionary Emprint™ SX ablation platform with Thermosphere™ technology by Medtronic.
  • The Emprint™ SX ablation platform combines real-time, 3D ultrasound and patented Thermosphere™ technology to treat non-resectable liver tumors .

NovaSure® V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe

Retrieved on: 
Wednesday, February 15, 2023
Medical Devices, Health, Consumer, Women, Health Technology, Biotechnology, Patient satisfaction, Woman, Use, Suction, GEA, Hologic, Patient, Hysterectomy, Ablation, FRCSC, International, Inc., HOLX, Multimedia, CHU, Birth control

Hologic Inc. (Nasdaq: HOLX), a global leader in women's health, has announced approval of the NovaSure® V5 global endometrial ablation (GEA) device in Canada and Europe.

Key Points: 
  • Hologic Inc. (Nasdaq: HOLX), a global leader in women's health, has announced approval of the NovaSure® V5 global endometrial ablation (GEA) device in Canada and Europe.
  • This innovative new version incorporates enhanced features designed to treat a wide range of cervical and uterine anatomies.
  • It builds on a world-class track record for NovaSure, including 3 million patients who have benefited from the device.
  • View the full release here: https://www.businesswire.com/news/home/20230215005183/en/
    NovaSure® V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe (Photo: Business Wire)
    “Since its launch over 20 years ago, we have constantly listened to our customers’ feedback, which has driven continuous design improvements for NovaSure,” said Jan Verstreken, Group President, International at Hologic.

Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter

Retrieved on: 
Monday, February 6, 2023
Arrhythmia, CE marking, Safety, Thermal conductivity, Gold, Pulmonary vein, PMA, AFIB, Ablation, Kishan Chand Parwani, Clinical study design, Atrial flutter, IDE, Physician, Catheter ablation, Patient, Blazer, Platinum, Cardiology (journal), Superior, Cardiology, Electrophysiology, Baptist Health, Atrial fibrillation, Temperature, Medical imaging, Pharmaceutical industry

“AcQBlate’s novel gold tip ablation catheter performed extremely well during the clinical IDE atrial flutter cases.

Key Points: 
  • “AcQBlate’s novel gold tip ablation catheter performed extremely well during the clinical IDE atrial flutter cases.
  • The AcQBlate FORCE sensing ablation catheter and system, which received CE Mark in 2020, is commercially available in Europe.
  • The AcQBlate FORCE sensing ablation catheter was designed to provide consistent, effective therapeutic delivery during cardiac ablation procedures.
  • AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter.

Laser Marking Global Market Report 2022: Growing Focus on Industry 4.0 Initiatives Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022
Technology, Hardware, Market share analysis, JPY, Aerospace, CHF, Defense, AUD, Business Growth Fund, GBP, Ceramic, Glass, Plastic, Laser, Strategic management, Research, Fiber laser, Value, Metal, Linear code, Growth, AGC Aerospace & Defense, Hardware, Carbon, Application, Customer support, Use, Barcode, Paper, CAD, USD, Engraving, Acquisition, Cryptocurrency, Retail, Ablation, Software, Electronics, Automotive industry, Health care, EUR

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.

Key Points: 
  • The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.
  • This research report categorizes the Laser Marking to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Offering, the market was studied across Hardware, Services, and Software.
  • Based on Laser Type, the market was studied across CO2 Laser, Diode Laser, Fiber Laser, and Solid-state Laser.
  • Based on Machine Type, the market was studied across 2D Laser Marking and 3D Laser Marking.

U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights

Retrieved on: 
Thursday, August 11, 2022
Medical Devices, Surgery, Patent Law, Health Technology, Professional Services, Other Health, Biotechnology, Radiology, Health, Oncology, FDA, Woman, List, Patient satisfaction, United States Court of Appeals for the Federal Circuit, Name, Science, Hormone, Patent, Patient, Acquisition, AUB, Hysterectomy, News, Supreme, Physician, Ablation, HOLX, Nasdaq, Solution, Supreme court, Health, Private law, Online gambling, Medical imaging, Appeal, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic.
  • In 2018, a Delaware district court found Minerva liable for patent infringement and barred the companys invalidity defenses under assignor estoppel.
  • Todays decision by the U.S. Court of Appeals is the latest decision in Hologics favor on this matter.
  • In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel.

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Retrieved on: 
Wednesday, July 27, 2022
Diagnosis, Treatment, Atrial tachycardia, GLOBE, Physician, Utility, Sensor, Mapping, AFIB, Human, VisionMap A3 Digital Mapping System, Arrhythmia, Extended play, CEO, Catheter, Tachycardia-induced cardiomyopathy, The New Possibility, Atrial fibrillation, Map, Patient, Heart, Electrophysiology, Ablation, Biofeedback Certification International Alliance, Growth, Medical imaging, Medical device, Juncus acutus

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced approval of its AcQMap High Resolution Imaging and Mapping System and the AcQMap 3D Imaging and Mapping Catheter in Japan.

Key Points: 
  • CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced approval of its AcQMap High Resolution Imaging and Mapping System and the AcQMap 3D Imaging and Mapping Catheter in Japan.
  • The AcQMap System and Catheter clearance represents a major advancement in the tools available to EPs in Japan, said David Roman, President & CEO of Acutus Medical.
  • The AcQMap 3D Imaging and Mapping Catheter are the cornerstones of Acutus innovative mapping platform as the worlds only integrated ultrasound-based imaging and non-contact mapping catheter capable of capturing cardiac imaging information and cardiac activation mapping, all without touching the heart.
  • At the center of the BIOTRONIK/Acutus Alliance for Electrophysiology lies the groundbreaking AcQMap High Resolution Imaging and Mapping System.

Oncology Information System Market Report 2022: Consulting & Optimization Services Present Opportunities

Retrieved on: 
Tuesday, July 12, 2022
Overalls, IORT, Ablation, Neoplasm, Radiation, EBRT, Solution, OIS, Health care, National Cancer Institute, Database, Software, Hospital, Co-production (public services), Adoption, Growth, Brachytherapy, Cancer, Efficiency, Medical device, Medical imaging, Application

Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.

Key Points: 
  • Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.
  • Moreover, the development of a wide range of novel technologies will bring significant opportunities for the oncology information system market during the forecast period.
  • The software segment accounted for 83.6% of the oncology information system market for products and services in 2021.
  • In 2021, the radiation oncology segment accounted for 53.8% of the oncology information system market for application.

Oncology Information System Market Report 2022: Growing Adoption of EHRS and Other Oncology Healthcare IT Solutions to Improve Care Quality Driving Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, July 8, 2022
Software, Technology, Health, Oncology, Efficiency, Adoption, Hospital, Growth, EBRT, Cancer, Radiation, Health care, Brachytherapy, Overalls, National Cancer Institute, Software, Neoplasm, Solution, Ablation, Database, OIS, IORT, Medical imaging, Application

Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.

Key Points: 
  • Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.
  • Moreover, the development of a wide range of novel technologies will bring significant opportunities for the oncology information system market during the forecast period.
  • The software segment accounted for 83.6% of the oncology information system market for products and services in 2021.
  • In 2021, the radiation oncology segment accounted for 53.8% of the oncology information system market for application.

Global Cardiac Ablation Market Trajectory & Analytics Report 2022: Market to Reach $1.7 Billion by 2027 - Emerging Markets Forecast to Post High Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Health, Cardiology, Cryoablation, COVID-19, Growth, Ablation, CAGR, Radio frequency, Catheter, Pet

The "Cardiac Ablation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Ablation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Radiofrequency (RF) Ablation, one of the segments analyzed in the report, is projected to record a 11.2% CAGR and reach US$900.2 Million by the end of the analysis period.
  • In the global Cryoablation segment, USA, Canada, Japan, China and Europe will drive the 9.9% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$139 Million by the year 2027.

EDDA Technology is proud to announce IQQA®-BodyImaging Provides 3D assessment in ACCLAIM Trial conducted by SIO

Retrieved on: 
Monday, April 18, 2022
CEO, MWA, Board, Technology, WCIO, Research, MR, Hospital, Education, Confirmation, Review, Director, Radiation, Intervention, Society, Ecosystem, CT, Ablation, SIO, 3D, Nominal interest rate, Interventional oncology, Transplant, IO, Physician, EDDA, Association, Medical imaging

IQQA-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.

Key Points: 
  • IQQA-BodyImaging Interventional will be used to provide 3D assessment of the ablation zone and margin for selected colorectal liver metastases.
  • The ACCLAIM study will estimate disease-free survival of colorectal liver metastases treated with MWA incorporating 3D ablation software (EDDA Technology) margin confirmation intraoperatively and through a subsequent independent review centralized validation process.
  • The IQQAplatform provides comprehensive 3D image analysis using MR and CT, and has been used in over 80,000 cases worldwide for surgery and treatment with substantial time-saving.
  • The Society of Interventional Oncology (SIO) is a non-profit association that supports and promotes the field of interventional oncology (IO).